CHC Intelligence · public-source snapshot · August 2026
Global Healthcare Capital Markets & M&A Insights
A curated view of announced healthcare transactions, capital-markets activity and strategic partnerships — spanning biopharma, AI-enabled R&D, MedTech, manufacturing and clinical services. Figures are dated public disclosures, not estimated market totals.
Capital markets pulse21 US biotech IPOs priced YTDHK$2.1B METiS TechBio · HKEX AI drug-delivery IPO
XBI Biotech
162.38
−3.48% · 28 Aug close
IBB Biotech
215.21
−0.55% · 26 Aug close
US biotech IPOs
21
priced through 26 Aug
Gross IPO proceeds
~$6.5B
US biotech · YTD
Largest biotech IPO
$670M
Parabilis Medicines
Gossamer financing
Up to $250M
structured private placement
Biopharma
M&A transactions, licensing deals, IPOs & financing, and strategic partnerships across the global biopharma landscape
Public-deal snapshot • updated 29 August 2026
Large-cap life-science transaction
Merck KGaA to Acquire Bio-Techne — $11.3B Enterprise Value
Merck KGaA, Darmstadt, Germany agreed to acquire Bio-Techne for $73 per share in cash. The proposed transaction brings research, biopharma and diagnostic workflow technologies into Merck KGaA’s life-science portfolio.
$73 per share
Cash Consideration
$11.3B EV
Enterprise Value
25 Jun 2026
Announced
Recent M&A & corporate transactions
Acquisition25 Aug 2026
McKesson to Acquire Precision Medicine Group
McKesson signed a definitive agreement to acquire the clinical-research and biopharma-commercialisation services provider, bringing biomarker intelligence, lab services, CRO and market-access capabilities into its oncology and multispecialty business.
Acquisition10 Aug 2026
Jazz Pharmaceuticals to Acquire Actio Biosciences
Jazz agreed to acquire Actio and its KCNT1+ epilepsy programme, ABS-1230, a clinical-stage precision small molecule for a rare developmental and epileptic encephalopathy.
Completed27 Aug 2026
argenx Completes Forte Biosciences Acquisition
argenx completed its acquisition of Forte, adding FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and coeliac disease, to its immunology pipeline.
Completed6 Aug 2026
Biogen Completes RayThera Acquisition
Biogen completed the purchase of RayThera, adding small-molecule immunology assets; the lead programme entered Phase 1 development in July.
All-stock deal16 Jul 2026
Jasper Therapeutics Acquires Kira Pharmaceuticals
Jasper closed the all-stock acquisition of Kira to form an immunology-focused clinical-stage portfolio; the transaction was accompanied by a $132 million PIPE.
Skye agreed to acquire Redx through a UK scheme of arrangement. The planned Nasdaq-listed combined company, Fibrx Therapeutics, is expected to focus on fibrosis.
Strategic partnerships & asset transactions
Asset purchase10 Aug 2026
Oculis & Accure — Privosegtor / ACT-02 Rights
Oculis signed to acquire worldwide development and commercial rights to Privosegtor and, separately, ACT-02. The structure removes the legacy licence arrangement and associated milestone and royalty obligations.
AI partnership10 Aug 2026
Novo Nordisk & AWS — Drug Discovery AI
Novo Nordisk named AWS its preferred cloud provider and strategic AI partner. Their London co-innovation hub applies AI and life-sciences tools from target identification through clinical-trial design.
Supply agreement3 Aug 2026
Taysha & Catalent — TSHA-102 Manufacturing
Taysha expanded its relationship with Catalent for future commercial manufacturing support of TSHA-102, an AAV gene therapy in pivotal development for Rett syndrome.
Facility acquisition10 Aug 2026
Xcellon Biologics Acquires NextCure GMP Facility
Xcellon agreed to acquire NextCure’s GMP biologics site, creating an end-to-end CRDMO platform for bioconjugates and complex biologics from discovery through clinical supply.
IPO & Financing
Company
Exchange
Raised
Ticker
Month
Focus
Vogenx US
NASDAQ
$81.3M
—
11 Aug 2026
Phase 2 metabolic / endocrinology
Latigo Biotherapeutics US
NASDAQ
$345.6M
LTGO
6 Aug 2026
Phase 3-ready non-opioid pain
BlossomHill Therapeutics US
NASDAQ
$150M
BLSM
6 Aug 2026
EGFR-mutant NSCLC / AML
Braveheart Bio US
NASDAQ
$382.5M
BRVE
5 Aug 2026
Phase 3-ready cardiovascular
Attovia Therapeutics US
NASDAQ
$289M
ATTO
4 Aug 2026
Immunology / dermatology biologics
Parabilis Medicines US
NASDAQ
$670M
—
10 Jun 2026
Phase 1/2 peptide therapeutics
Kailera Therapeutics US
NASDAQ
$625M
—
16 Apr 2026
Phase 3 obesity / metabolic disease
HKEX biotech watch HKEX
METiS TechBio raised more than HK$2.1B in May, the largest healthcare IPO in Hong Kong so far in 2026. HKEX also reports 84 Chapter 18A biotech listings at end-January 2026 and more than US$17.5B in biotech IPO fundraising since its 2018 reforms.
METiS TechBioHK$2.1B AI-powered drug-delivery IPO · May 2026
Chapter 18A ecosystem84 listed biotechs at end-Jan 2026 · US$17.5B+ raised since reform
AI Drug Discovery
AI-enabled R&D is moving from point tools to integrated discovery, data and clinical-development workflows across the biopharma value chain
Public partnership snapshot • updated 29 August 2026
Recent strategic AI partnership
Novo Nordisk & AWS — Agentic AI for Drug Discovery
Novo Nordisk and AWS announced a strategic partnership and London co-innovation hub to apply cloud and agentic AI across research and development. The collaboration connects genomic, imaging and clinical data to target discovery, therapy design and clinical-trial planning.
AWS preferred cloud
Strategic AI Partner
London co-innovation hub
Operating Model
10 Aug 2026
Announced
Recent AI-enabled R&D collaborations
Software collaboration5 Aug 2026
Schrödinger & Bristol Myers Squibb — Bunsen AI
BMS will deploy Schrödinger’s agentic AI co-scientist, Bunsen, across its research organisation and collaborate on capabilities for large-scale chemical exploration and AI-driven synthesis planning.
Odyssey will use Evotec’s data-driven discovery platform, screening capabilities and AI-enabled data science to discover and validate small-molecule candidates across high-value autoimmune and inflammatory targets.
Discovery milestone5 Aug 2026
Recursion & Genentech — First Neuroscience Target
Genentech advanced the first neuroscience target from its collaboration with Recursion into an early discovery programme, moving an AI-driven biology-map output into hit generation and validation.
Strategic partnership10 Aug 2026
Novo Nordisk & AWS — Discovery Co-innovation Hub
Novo Nordisk selected AWS as preferred cloud provider and strategic AI partner. Their London hub brings engineers and scientists together to shorten the path from target identification to first human dose.
Platform and capital-markets activity
Corporate formation3 Aug 2026
Lantern Pharma Establishes Open-Medicine AI
Lantern established Open-Medicine AI as a separate company to commercialise and expand its multi-agent AI co-scientist platform, with commercial licences covering relevant models, data and algorithms.
Research partnership7 Aug 2026
Owkin & CRO Aviano — Oncology Data Partnership
Owkin and the Italian National Cancer Institute CRO Aviano signed a master partnership agreement to enable collaborative oncology research, data digitalisation and the use of AI in scientific workstreams.
IPO26 Feb 2026
Generate Biomedicines — US Biotech IPO
Generate Biomedicines raised $400 million in its US IPO. The company is developing protein therapeutics using a generative-biology platform; its lead anti-TSLP programme was in Phase 3 at pricing.
Regulatory signal18 Aug 2026
FDA Seeks Input on Generative-AI Medical Devices
The FDA opened a public-feedback process to inform its regulatory approach for generative-AI-enabled medical devices, a useful policy signal for the wider healthcare AI ecosystem.
MedTech
Medical device, diagnostics and digital health — M&A, licensing, IPOs & financing, partnerships and expansion
Public-deal snapshot • updated 29 August 2026
Latest disclosed imaging transaction
Teledyne to Acquire Varex Imaging — ~$1.1B
Teledyne and Varex signed a definitive agreement for Teledyne to acquire Varex at $18.90 per share in cash. Varex supplies X-ray tubes, flat-panel and photon-counting detectors and imaging software used across diagnostic imaging and other technical markets.
$18.90 per share
Cash Consideration
~$1.1B value
Transaction Value
Early 2027
Expected Completion
Recent MedTech & healthcare-services transactions
Acquisition20 Jul 2026
Cardinal Health to Acquire AdaptHealth’s Diabetes Business
AdaptHealth agreed to sell substantially all assets of its diabetes medical-device and related-services business to Cardinal Health, subject to customary closing conditions.
Acquisition7 Jul 2026
Frazier Healthcare Partners to Acquire ResMed’s MatrixCare
ResMed agreed to sell MatrixCare to Frazier Healthcare Partners, sharpening its focus on sleep, breathing and connected home health. MatrixCare provides software to more than 15,000 care providers.
Acquisition10 Aug 2026
Teledyne to Acquire Varex Imaging
Teledyne agreed to acquire Varex at $18.90 per share in cash. Varex supplies X-ray tubes, detectors, high-voltage interconnects and imaging software for diagnostic-imaging and other technical applications.
Acquisition27 Aug 2026
hVIVO Acquires CRS Berlin
hVIVO acquired the specialist Phase I/II research unit to add dermatology and women’s-health capability. CRS Berlin brought a contracted orderbook of about €10 million.
Acquisition10 Aug 2026
Kyndryl to Purchase Healthcare IT Leaders
Kyndryl announced its intent to acquire Healthcare IT Leaders to deepen healthcare application, infrastructure and AI-led modernisation services for hospitals and health systems.
Market and regulatory signals
Market update29 Jul 2026
GE HealthCare — Q2 Order Momentum
GE HealthCare reported 11.1% organic orders growth in Q2 2026 and a $23.9 billion backlog, with order growth across every segment.
Regulatory signal25 Aug 2026
FDA Authorizes Dual Ketone and Glucose Wearable
The FDA authorised the first wearable device that continuously monitors both ketone levels and blood sugar, a notable regulatory milestone for continuous metabolic monitoring.
CDMO & CRO
Global contract development, manufacturing, and clinical research organisations — M&A, capacity expansions, partnerships and new service models
Public infrastructure snapshot • updated 29 August 2026
Recent manufacturing infrastructure transaction
Xcellon Biologics Acquires NextCure GMP Facility
Xcellon signed to acquire NextCure’s GMP biologics manufacturing facility, adding integrated discovery, bioconjugation, process-development, analytical and clinical-supply capabilities. The site is intended to establish an end-to-end CRDMO platform for complex biologics.
40,000 sq ft
Facility Footprint
2 × 1,000L single-use
Bioreactors
Dec 2026
GMP Operations Target
CDMO & Manufacturing Partnerships
CDMO10 Aug 2026
Xcellon Biologics — NextCure GMP Facility
The acquisition adds a 40,000-square-foot GMP site with two 1,000-litre single-use bioreactors, a bioconjugation suite and analytical laboratories, expanding Xcellon from specialised services to an integrated CRDMO model.
CDMO3 Aug 2026
Taysha & Catalent — TSHA-102 Commercial Supply
Taysha expanded its strategic partnership with Catalent for future commercial manufacturing support of TSHA-102, an investigational AAV gene therapy in pivotal development for Rett syndrome.
CDMO25 Aug 2026
Catalent — Growth and Innovation Refinancing
Catalent completed a refinancing comprising a $4.1 billion equivalent seven-year Term Loan B and a $600 million revolving credit facility, replacing its existing Term Loan B and supporting continued investment in the CDMO network.
CDMO1 Jul 2026
Lonza Expands Strategic US Biopharma Collaboration
Lonza expanded a strategic partnership with a leading US biopharmaceutical company, adding commercial biologics programmes and options for further programmes across its US and European manufacturing network.
CDMO24 Aug 2026
Scinai — CDMO Customer-Order Growth
Scinai reported approximately $3.1 million of committed customer orders at 16 August 2026, alongside expansion of its clinical-manufacturing and CMC programme for a US biopharmaceutical customer.
CDMO16 Jun 2026
Catalent Launches Qai Quality-Assurance Tool
Catalent launched Qai, an enterprise AI tool intended to support quality-assurance systems and processes across its manufacturing-services network.
Clinical Research Organisations (CRO)
CRO acquisition25 Aug 2026
McKesson to Acquire Precision Medicine Group
McKesson’s planned acquisition of Precision Medicine Group adds a global CRO, biomarker intelligence, laboratory services, market-access consulting and commercialisation support to its oncology and multispecialty platform.
CRO18 Aug 2026
Curavit Acquires Lindus Health CRO Assets
Curavit acquired Lindus Health’s CRO assets to create unified US and European trial-delivery capabilities across decentralised, hybrid and traditional studies.
CRO27 Aug 2026
hVIVO Acquires CRS Berlin
hVIVO acquired the Phase I/II research unit, expanding its clinical-trial capability in dermatology and women’s health. The target had a contracted orderbook of roughly €10 million.
CRO7 Aug 2026
Owkin & CRO Aviano — Oncology Research Partnership
Owkin and CRO Aviano agreed to develop collaborative oncology research projects, including data digitalisation and the use of AI as a scientific and technology workstream.
China Healthcare | H1 2026
A source-based view of innovation output, cross-border licensing, AI-enabled R&D and healthcare capital formation.
Public-source snapshot • H1 2026
H1 2026 market pulse
Innovation is translating into global deal flow.
China’s innovative-drug ecosystem is pairing rapid regulatory output with a record level of cross-border partnering. The headline figures below are potential announced values, not cash paid at signing.
81
innovative-drug out-licensing deals
$110B
potential out-licensing value
38
innovative drugs approved in H1
31
approvals developed domestically
$18.5B
CSPC / AstraZeneca
Potential value across eight long-acting peptide programmes, AI discovery and delivery platforms.
licensing
HK$2.1B
METiS TechBio
Hong Kong’s largest healthcare IPO so far in 2026; an AI-powered drug-delivery company.
HKEX IPO
+6.4%
Pharma output
H1 year-on-year growth in value-added output; biopharmaceutical output recorded double-digit growth.
industry
+9%
Export delivery
H1 growth in pharmaceutical export delivery value, which exceeded RMB 210B.
exports
Out-licensing is now a core financing channel
H1 potential deal value reached roughly 80% of 2025’s full-year total. Oncology, metabolism, immunology and neurology featured prominently in the 81 announced cross-border agreements.
AI platform science is reaching public markets
METiS’s HKEX debut offers a concrete capital-markets marker for China’s AI-for-science ecosystem, spanning drug delivery, molecular design and specialist platform technologies.
Regulatory and industrial execution remain decisive
Thirty-eight innovative drugs were approved in H1, including 31 domestic programmes, while manufacturing output and export delivery continued to grow alongside the innovation pipeline.
Sources: NMPA / NHSA, MIIT public H1 disclosures, company announcements and HKEX filings. Licensing figures include potential development, regulatory and commercial milestones where disclosed.
CHC Intelligence Platform
BioAccess⭐
The intelligence layer for science and capital — bringing biotech asset access, transaction analysis, industry insights and AI-assisted screening into one connected workflow.
Disclaimer: This database is provided for informational purposes only and does not constitute investment advice or an offer or solicitation to purchase or sell any securities. All asset data is based on proprietary research by CHC. CHC Intelligence serves as the data and analytics platform of CHC Capital Partners.
Deep research
Context behind the asset — not just the row in a database.
Focused research notes bring together clinical context, competitive signals and transaction relevance, so a search result can become an investment or partnering conversation.
REPORT 01JUN 2026
Oncology
China ADC Landscape: The Next Wave of Global Licensing
Why target selection, payload innovation and clinical velocity are reshaping the ADC partnering market.
Prioritise differentiated linker–payload combinations and manageable safety profiles.
Read cross-border licensing activity alongside clinical readouts, not in isolation.
Look for global development rights, optionality and manufacturing scale.
Review manufacturing scale and geographic access as part of the value thesis.
Transaction database
China biotech transactions, structured for comparison.
Searchable licensing, M&A, NewCo and partnership activity captures deal architecture alongside the scientific asset, modality and therapeutic focus.
Loading deals
China biotech / partner
Asset / target
Deal value
Modality
Type
Date
Data coverage: Publicly announced licensing, NewCo, M&A and partnership transactions involving China-based biotech companies. Deal values reflect disclosed potential consideration, including upfront and milestone components where reported. Data should be independently verified before use in a transaction or investment decision.
AI models
Screen the BioAccess universe with an explainable signal layer.
Use a transparent, client-side triage model to surface assets by clinical maturity, modality, therapeutic area and licensing availability. Results are decision support — not a clinical or investment recommendation.
Asset screener
Filter by therapeutic area, modality and clinical stage to generate a ranked shortlist.
EXPLAINABLE MODEL
Ready to screenSignal score · 0–99
Choose criteria, then generate a ranked shortlist.
CHC Dispatch · Weekly healthcare briefing
The week in healthcare, distilled.
Each week, get a concise briefing on biotech assets, deals, clinical catalysts, market developments, and expert insights—built for decision-makers.
Get full access to the BioAccess asset database, deep research, biotech transaction intelligence, and AI-assisted screening tools. Looking for our free weekly newsletter? Subscribe here — no payment required.
What's Included
Full access to CHC-tracked therapeutic assets
Browse, search and filter by area, modality and stage
Licensing, regulatory and clinical-stage signals
“Recently updated” flags and rolling data refresh
Curated “emerging licensing candidates”
Bi-weekly new-asset and clinical-catalyst email alerts
Deep research across priority therapeutic areas
China biotech transaction database and deal context
Explainable AI-assisted asset screening
Full access to future BioAccess database expansion
Platform-only access — no export or download
Cancel anytime, no questions asked
Monthly
$2,999
per month
QuarterlyMost Popular
$6,999
per quarter $2,333/mo — Save 22%
YearlyBest Value
$18,999
per year $1,583/mo — Save 47%
Secure payment via Stripe • Cancel anytime • No hidden fees
Global Vision. Local Expertise. Trusted Partners.
Healthcare M&A & Strategic Advisory across global markets with deep sector expertise.
Contact Us
Subscribe to the CHC Dispatch newsletter
Get CHC Intelligence's latest healthcare insights delivered to your inbox every week. No payment required.
Create Account
Join CHC Intelligence for full access to deal analytics, asset databases, and exclusive market insights.